Drug Database
Back to search

France· FR:69945545

SIVEXTRO 200 mg, comprimé pelliculé

A tedizolid product containing phosphate de tédizolid, registered in France by MERCK SHARP & DOHME (PAYS-BAS). The same ATC class is registered in 14 of our 19 countries.

ATC J01XX11

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedSIVEXTRO 200 mg, comprimé pelliculéATCJ01XX11REGISTER NO.FR:69945545PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about phosphate de tédizolidAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tedizolid is registered in 14 of 19 countries.

Countries holding a registration under ATC J01XX11 (tedizolid), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose
Search tedizolid products by name

Tedizolid · ATC J01XX11

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tedizolid costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Tedizolid · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • IT Italy$346.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
PHOSPHATE DE TÉDIZOLID
Manufacturer
MERCK SHARP & DOHME (PAYS-BAS)
Country
France (FR)
ATC code
J01XX11
ATC class
Tedizolid
Defined daily dose
0.2 g, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930011140
    6 plaquette(s) aluminium PVC PVDC de 1 comprimé(s)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

51 interactions on record for tedizolid.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tedizolid against other medicinesHow interaction checks work

Tedizolid · interactions on record

51 records

  • 2 severe
  • 49 moderate

Most severe, free to view

  • OzanimodL04AA38severe
  • OzanimodL04AE02severe
  • Sodium picosulfateA06AB08moderate
  • SulfasalazineA07EC01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tedizolid in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tedizolid products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sivextro
  • Liechtenstein · Sivextro
  • Norway · Sivextro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/02f053ef-6f55-413f-8143-78c23c49e10d
GET /v1/drugs/02f053ef-6f55-413f-8143-78c23c49e10d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69945545",
  "date_amm": "2015-03-23",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/15/991",
  "substance": "PHOSPHATE DE TÉDIZOLID",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about tedizolid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console